PMID- 32193837
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 11
IP  - 5
DP  - 2020 May
TI  - Once-Weekly Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 
      Diabetes Regardless of Background Common OAD: a Subgroup Analysis from 
      SUSTAIN 2-4 and 10.
PG  - 1061-1075
LID - 10.1007/s13300-020-00796-z [doi]
AB  - INTRODUCTION: Despite treatment with oral antidiabetic drugs (OADs), achieving 
      effective glycaemic control in type 2 diabetes (T2D) remains a challenge. The 
      objective of this post hoc analysis of data from the SUSTAIN 2, 3, 4 and 10 
      active-controlled trials was to assess the efficacy and safety of the once-weekly 
      glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide in patients on 
      background treatment with metformin (MET), with or without a sulphonylurea (SU). 
      METHODS: Data from the randomised phase 3 trials SUSTAIN 2, 3, 4 and 10 for 
      subjects who received background MET alone or MET + SU were analysed. Change from 
      baseline in HbA(1c) and body weight at the end of treatment visit (week 30 in 
      SUSTAIN 4 and 10, week 56 in SUSTAIN 2 and 3), and rates of hypoglycaemia and 
      adverse events leading to premature treatment discontinuation were assessed. 
      RESULTS: In total, 3411 subjects were included in the full analysis set (3410 in 
      the safety analysis set). Across the four trials, semaglutide significantly 
      reduced HbA(1c) (estimated treatment difference [ETD] - 0.32 to - 0.79%-points 
      for semaglutide 0.5 mg, and - 0.38 to - 1.07%-points for semaglutide 1.0 mg vs 
      comparators; p < 0.01) in subjects receiving both MET and MET + SU. Regardless of 
      background OAD, semaglutide significantly reduced body weight (ETD - 2.35 to 
      - 4.72 kg for semaglutide 0.5 mg, and - 2.96 to - 6.76 kg for semaglutide 1.0 mg 
      vs comparators; p < 0.0001). Across the trials, hypoglycaemic events were more 
      common with background MET + SU than MET alone, in subjects receiving either 
      semaglutide or a comparator. The rate of adverse events (AEs) leading to 
      premature treatment discontinuations in subjects treated with semaglutide were 
      generally consistent regardless of background therapy. CONCLUSION: Semaglutide 
      0.5 mg and 1.0 mg significantly improve glycaemic control (HbA(1c)) and body 
      weight in subjects with T2D, with a similar tolerability profile, regardless of 
      whether they receive background MET or MET + SU. TRIAL REGISTRATION: 
      Clinicaltrials.gov: NCT01930188 (SUSTAIN 2), NCT01885208 (SUSTAIN 3), NCT02128932 
      (SUSTAIN 4) and NCT03191396 (SUSTAIN 10).
FAU - Capehorn, Matthew
AU  - Capehorn M
AD  - Rotherham Institute for Obesity (RIO), Clifton Medical Centre, Rotherham, South 
      Yorkshire, UK. mcapehorn@yahoo.co.uk.
FAU - Ghani, Yasmin
AU  - Ghani Y
AD  - Novo Nordisk A/S, London, UK.
FAU - Hindsberger, Charlotte
AU  - Hindsberger C
AD  - S-cubed APS (contracted by Novo Nordisk A/S), Copenhagen, Denmark.
FAU - Johansen, Pierre
AU  - Johansen P
AD  - Novo Nordisk A/S, Soborg, Denmark.
FAU - Jodar, Esteban
AU  - Jodar E
AD  - Hospital Universitario Quiron Salud Madrid, Universidad Europea de Madrid, 
      Madrid, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT03191396
SI  - ClinicalTrials.gov/NCT01885208
SI  - ClinicalTrials.gov/NCT01930188
SI  - ClinicalTrials.gov/NCT02128932
PT  - Journal Article
DEP - 20200319
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC7193006
OTO - NOTNLM
OT  - Diabetes care
OT  - GLP-1RA
OT  - Metformin
OT  - Oral antidiabetic agents
OT  - Randomised controlled trials
OT  - Semaglutide
OT  - Sulphonylurea
OT  - Type 2 diabetes
EDAT- 2020/03/21 06:00
MHDA- 2020/03/21 06:01
PMCR- 2020/03/19
CRDT- 2020/03/21 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/03/21 06:00 [pubmed]
PHST- 2020/03/21 06:01 [medline]
PHST- 2020/03/21 06:00 [entrez]
PHST- 2020/03/19 00:00 [pmc-release]
AID - 10.1007/s13300-020-00796-z [pii]
AID - 796 [pii]
AID - 10.1007/s13300-020-00796-z [doi]
PST - ppublish
SO  - Diabetes Ther. 2020 May;11(5):1061-1075. doi: 10.1007/s13300-020-00796-z. Epub 
      2020 Mar 19.